Full-Time

Generative AI Platform Architect

Evinova

Updated on 9/3/2026

AstraZeneca

AstraZeneca

10,001+ employees

Global pharmaceutical company developing prescription medicines

Compensation Overview

$167.8k - $251.7k/yr

+ Short-term incentive bonus + Equity-based long-term incentive program + Commission payment eligibility

Gaithersburg, MD, USA

Hybrid

Comprehensive relocation packages available for qualified candidates.

Category
DevOps & Infrastructure (1)
Required Skills
LLM
Kubernetes
Python
Airflow
NoSQL
SQL
TypeScript
Microservices
AWS

Get referred to AstraZeneca

See people who can refer or advise you

Requirements
  • HS Diploma and 8 years of experience in Engineering/IT solutions OR BA/BS Degree and 6 years of experience or equivalent capabilities.
  • Minimum of 10 years in cloud infrastructure design and management roles.
  • Deep understanding of the Data Science Lifecycle (DSLC) and the ability to shepherd data science projects from inception to production within the platform architecture.
  • Expert in TypeScript, AWS CDK, Projen, and Argo CD and other Cloud Infrastructure CI/CD Tools
  • Strong familiarity with Python
  • Extensive experience in managing Kubernetes clusters and/or ECS for GenAI workflows.
  • Solid understanding of foundation models and their applications in GenAI solutions.
  • Strong background in AWS DevOps practices and cloud architecture.
  • Deep knowledge of AWS services (Bedrock, Sagemaker, EC2, S3, RDS, Lambda, etc) and hands-on design and implementation of cloud systems (microservices architecture, API design, and database management (SQL/NoSQL)
  • Experience with monitoring and optimizing cloud infrastructure for scalability and cost-efficiency.
  • Ability to collaborate effectively with engineering, design, product, science and security teams.
  • Strong written and verbal communication skills for reporting and documentation.
  • Demonstrated ability to manage large-scale, complex projects across an organization.
  • Proven experience in conducting performance and cost analyses of AWS infrastructure and ML/AI models.
Responsibilities
  • Lead by example in creating high-performance, mission-focused and interdisciplinary teams/culture founded on trust, mutual respect, growth mindsets, and an obsession for building extraordinary products with extraordinary people.
  • Drive the creation of proactive capability and process enhancements that ensures enduring value creation and analytic compounding interest.
  • Design and implement resilient cloud Generative AI and agentic system operational capabilities to maximize our system Learnability, Flexibility, Extendibility, Interoperability, Scalability.
  • Drive precision and systemic cost efficiency, optimized system performance, and risk mitigation with a data-driven strategy, comprehensive analytics, and predictive capabilities at the tree-and-forest level of our GenAI agent systems, workloads and processes.
  • Architect and implement scalable AWS agentic GenAI cloud infrastructure in a multi-tenant SaaS environment.
  • Deep understanding of challenges in deploying Generative AI applications and agents.
  • Closely follow frontier developments in Generative AI and GenAI tooling, techniques, and technologies.
  • Establish governance frameworks for agentic GenAI infrastructure management and ensure compliance with industry best practices.
  • Ensure principled and methodical validation pathways and a Well Architected Framework for Embryonic Research (WAFER) similar to and building on AWS’s Well Architected Framework (WAF) for all early stage product and operational GenAI PoC’s across the organization.
  • Oversee GenAI-related Kubernetes (k8s) cluster management and provide expertise on alternative GenAI workflow orchestration options such as Argo vs Kubeflow vs ECS vs AgentCore, and GenAI data pipeline creation, management and governance with tools like Airflow or others.
  • Employ tools like AWS CDK (TypeScript), Projen, and Argo CD to automate infrastructure deployment and management.
  • Help set the strategy and manage the tactical balance between framework and platform experimentation and democratization with standardization and centralized management and governance
  • Conduct cost-benefit analyses and formal processes for selection and utilization of foundation models, evaluating their architectures, performance, and costs.
  • Work with multiple teams to ensure that the platform meets organizational needs and scales effectively.

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Get referred to AstraZeneca

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 2026 Federal Circuit upheld Tagrisso, protecting a core lung-cancer franchise.
  • April 2026 FDA approved Saphnelo autoinjector, expanding lupus access across 70 countries.
  • August 2026 Tezspire succeeded in eosinophilic esophagitis, opening another blockbuster indication.

What critics are saying

  • April 30, 2026 FDA advisers rejected camizestrant, threatening AstraZeneca's next breast-cancer launch.
  • Forxiga faces patent defeats in Poland and Portugal, with France and Australia trials pending.
  • If camizestrant fails and Tezspire stalls, AstraZeneca's 2030 $80 billion target collapses.

What makes AstraZeneca unique

  • AstraZeneca pairs oncology scale with immunology blockbusters like Imfinzi, Enhertu, and Tezspire.
  • Its 2026 UK investment keeps Cambridge and Macclesfield tightly linked to discovery and manufacturing.
  • The company commercializes partnered assets globally, sharing risk with Amgen and Daiichi Sankyo.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

4%
Yahoo Finance
Sep 8th, 2026
AstraZeneca shares slip 0.7% despite Imfinzi trial success in lung cancer treatment

AstraZeneca shares declined approximately 0.7% to $161.51 despite positive late-stage trial results for Imfinzi in treating extensive-stage small-cell lung cancer. The 563-patient DeLLphi-305 trial met its primary overall-survival goal when Imfinzi was combined with Amgen's Imdelltra, also improving progression-free survival and response rates with no new safety concerns. However, the companies have not released numerical survival data, leaving investors unable to assess the treatment's competitive strength. Imfinzi generated $6.06 billion in 2025, whilst oncology represented approximately 46% of AstraZeneca's $30.7 billion first-half 2026 revenue. The shares now trade 10.72% below their $180.91 valuation estimate. AstraZeneca must share economics with Amgen and demonstrate that the treatment's added complexity can convert into meaningful sales growth.

International Society for Pharmaceutical Engineering (ISPE)
Sep 2nd, 2026
Inside AstraZeneca's 2026 ISPE Facility of the Year Awards (FOYA) Social Impact - Unmet Medical Needs Category award-winning project: Commercial Cell Therapy Facility.

Inside AstraZeneca's 2026 ISPE Facility of the Year Awards (FOYA) Social Impact - Unmet Medical Needs Category award-winning project: Commercial Cell Therapy Facility. AstraZeneca's Commercial Cell Therapy Facility in Rockville, Maryland is setting a new benchmark for how pharmaceutical manufacturers can deliver lifesaving therapies while simultaneously advancing sustainability and operational excellence. Recognized as the 2026 ISPE Facility of the Year Awards (FOYA) Social Impact - Unmet Medical Needs Category Winner, the facility demonstrates how innovative engineering, risk-based design, and patient-centered thinking can transform commercial cell therapy manufacturing. Spanning 105,000 square feet across three stories, the fully electrified biomanufacturing facility was designed to support commercial-scale autologous T-cell therapy manufacturing and late-stage oncology clinical trials. More importantly, it was built around a singular mission: ensuring uninterrupted access to potentially lifesaving therapies for patients facing some of the most serious unmet medical needs in healthcare today. Why AstraZeneca won. Autologous cell therapies present unique manufacturing challenges unlike those found in traditional pharmaceutical production. Because each therapy is manufactured from an individual patient's own cells, every batch is personalized and irreplaceable. Unlike conventional medicines, inventory cannot be stockpiled for future use. If manufacturing is interrupted, the consequences may extend far beyond production delays. For many cell therapy patients, particularly those battling advanced cancers, treatment timelines are often measured in weeks or months. A manufacturing failure that compromises a patient-specific batch can eliminate a critical treatment opportunity at a moment when time is limited. Recognizing these realities, AstraZeneca established an ambitious and nonnegotiable design objective for its Rockville facility: 100 percent operational uptime with no facility-wide maintenance shutdowns. This requirement fundamentally shaped the project's design philosophy. Rather than relying on traditional pharmaceutical manufacturing standards alone, AstraZeneca and its project partners drew inspiration from industries where continuous operation is essential, including nuclear power generation, oil refining, and Tier IV data center infrastructure. The result is a facility engineered to achieve an extraordinarily high level of reliability. Through the application of quantitative risk assessments and layers of protection analysis, the team designed a system with a probability of total power loss of less than one event in 10,000 years. This achievement establishes a new reliability benchmark for commercial cell therapy manufacturing and reflects a deep commitment to protecting each patient's individualized treatment journey. Engineering resiliency around the patient. At the heart of the project is an important shift in perspective: every batch represents a patient. This patient-first philosophy influenced every aspect of facility design. The team systematically identified and eliminated single points of failure across critical infrastructure systems, including: * Electrical distribution systems * Mechanical infrastructure * Automation platforms * Process utilities * Building operations systems By creating redundancy throughout the facility, AstraZeneca significantly reduced the likelihood that infrastructure failures could disrupt manufacturing operations or jeopardize in-process therapies. The facility is designed to support treatment production for up to 4,000 patients annually, creating the capacity needed to bring personalized cancer therapies to a larger patient population while maintaining the reliability required for commercial-scale operations. The significance of this accomplishment extends beyond engineering. It represents a tangible investment in patient outcomes, helping ensure that individuals facing life-threatening diseases have reliable access to therapies that could improve or extend their lives. Redefining the relationship between resiliency and sustainability. Historically, highly resilient facilities have often relied on energy-intensive designs that increase environmental impact. AstraZeneca challenged this long-standing assumption. The Rockville facility demonstrates that operational resiliency and environmental stewardship can be complementary objectives rather than competing priorities. As a fully electrified biomanufacturing facility, the project was designed to support net-zero operational carbon performance while delivering exceptional reliability. The facility achieved: * A 50 percent reduction in energy consumption * A 50 percent reduction in water use * Net-zero operational carbon objectives * Fully electrified building systems These sustainability achievements are particularly noteworthy given the complexity and criticality of cell therapy manufacturing. The facility successfully combines advanced resiliency measures with resource-efficient technologies, creating a model that addresses both patient needs and broader environmental responsibilities. By proving that world-class reliability can coexist with aggressive sustainability goals, AstraZeneca has established a new paradigm for future pharmaceutical manufacturing facilities. A replicable blueprint for the Future of Cell Therapy manufacturing. Beyond its immediate operational impact, the Rockville facility serves as a model for the broader life sciences industry. The project successfully integrates cross-industry risk methodologies, advanced infrastructure design principles, and sustainable operating strategies into a scalable commercial manufacturing platform. These innovations create a framework that other organizations can adapt as demand for personalized medicines continues to grow. The facility demonstrates that patient-centered manufacturing can be achieved at commercial scale without compromising sustainability, operational performance, or long-term business viability. As cell and gene therapies continue to reshape modern healthcare, manufacturers face increasing pressure to deliver highly personalized treatments reliably, efficiently, and responsibly. AstraZeneca's project provides a practical roadmap for meeting those expectations. Most importantly, the facility reinforces a powerful message: protecting patients and protecting the planet can be achieved simultaneously through thoughtful design, innovation, and execution. A new standard for Social Impact in pharmaceutical manufacturing. By earning 2026 ISPE FOYA Social Impact - Unmet Medical Needs Category Winner recognition, AstraZeneca has demonstrated how innovative facility design can directly support better patient outcomes while advancing sustainability goals. The Commercial Cell Therapy Facility is more than a manufacturing plant. It is a patient-centered infrastructure platform engineered to protect every personalized therapy, eliminate avoidable interruptions, and ensure reliable access to potentially lifesaving treatments. Through unprecedented reliability standards, industry-leading sustainability performance, and a commitment to addressing unmet medical needs, AstraZeneca has established a new benchmark for commercial cell therapy manufacturing. As personalized medicines continue to transform healthcare, facilities like the Rockville site will play a critical role in ensuring patients receive the therapies they need without delay. AstraZeneca's award-winning project serves as a compelling example of how innovation, resiliency, and social responsibility can come together to create lasting impact for patients, communities, and the pharmaceutical industry as a whole.> ISPE Shape the Future of Pharma ISPE delivers technical and operational solutions to support across the global pharmaceutical and biopharmaceutical industry in the manufacture of quality medicines for patients.

Associated Press
Sep 1st, 2026
Enhertu plus pertuzumab approved in EU for HER2+ metastatic breast cancer, triggering $100M milestone

The European Union has approved Enhertu (trastuzumab deruxtecan) combined with pertuzumab as first-line treatment for HER2 positive metastatic breast cancer, marking the first new regimen in this setting in over a decade. The treatment, jointly developed by Daiichi Sankyo and AstraZeneca, is based on the DESTINY-Breast09 phase 3 trial. The trial showed the combination reduced disease progression or death risk by 44% compared to standard treatment. Median progression-free survival reached 40.7 months versus 26.9 months with conventional therapy. The European Commission approval follows a recent tumour agnostic approval for Enhertu in the EU. AstraZeneca will pay Daiichi Sankyo a $100 million milestone payment for this indication. The combination is now approved in over 40 countries worldwide for first-line treatment of HER2 positive metastatic breast cancer.

Xtalks
Aug 31st, 2026
From Oxfordshire to Wales: where UK Life Sciences investment is going in 2026.

From Oxfordshire to Wales: where UK Life Sciences investment is going in 2026. Cambridge is one of several UK life sciences hubs attracting new investment in R&D, manufacturing and biopharma infrastructure. From clinical cleanrooms in Birmingham to mRNA manufacturing in Oxfordshire, new investment is adding research and production capacity across the UK life sciences sector. The UK life sciences sector generates approximately $200 billion (£147 billion) in annual turnover and employs around 360,000 people. Nearly half of these jobs are located outside London, the East and South East of England. In July 2026, the UK government reported that the country had attracted more than $4.1 billion (£3 billion) in public-private life sciences investment over the previous 12 months. Pharma investment reaches Cambridge, Oxfordshire and surrey. AstraZeneca is investing approximately $408 million (£300 million) across its Cambridge headquarters and Macclesfield operations, including work using AI in drug discovery. Moderna has also opened its Innovation and Technology Centre at Harwell in Oxfordshire as part of its 10-year, around $1.36 billion (£1 billion) UK R&D commitment. The site combines clinical R&D with mRNA drug substance manufacturing and has capacity to produce up to 100 million vaccine doses during endemic periods, rising to 250 million during a pandemic. Around $680 million (£500 million) is being invested in UCB's new R&D and biologics manufacturing facility in Windlesham. The project is expected to support up to 240 jobs. Xtalks Insights Protected by reCAPTCHA. What topics would you like to hear more about? Select all that apply. Want to get even more specific? Help us narrow down the sub-topics that you're most interested in. For webinars, videos, podcasts and more from Xtalks, join our community today. Manufacturing investment extends across the UK. In April 2026, the UK government announced more than $109 million (£80 million) in investment across several life sciences manufacturing projects. Accord Healthcare is investing more than $61 million (£45 million) in Barnstaple, North Devon, to increase local production of newer medicines, including treatments for bipolar disorder, while maintaining its generic medicine operations. In Birmingham, approximately $13.6 million (£10 million) is going toward a near-patient biomanufacturing facility at the Precision Health Technologies Accelerator. The site will include three cleanrooms for medicines, vaccines and clinical trial materials, including cell and gene therapies and mRNA vaccines. In Wales, specialty pharmaceutical company Norgine is investing more than $27 million (£20 million) at its Hengoed site to expand production of gastrointestinal medicines and upgrade manufacturing capacity. Public investment is also being used to bring in private capital. The government says around $156 million (£115 million) allocated through the Life Sciences Innovative Manufacturing Fund has helped secure more than $894 million (£657 million) in private investment across 10 projects. Those projects are expected to create 487 jobs and safeguard another 1,330. In August 2026, the UK government released eligibility rules for its Life Sciences Large Investment Portfolio to encourage major life sciences projects in the country. To qualify for support, companies must plan to invest at least $340 million (£250 million) in UK-based R&D or manufacturing over three years, with at least one eligible project beginning within 12 months. If you want your company to be featured on Xtalks.com, please email [email protected].

Albemarle County
Aug 28th, 2026
County news.

County news. FY2026 Strategic Plan progress report. Post Date: 08/28/2026 8:30 AM Enablealbemarle has released its Fiscal Year 2026 Strategic Plan Execution Analysis Report (SPEAR), marking its third year of reporting significant achievements and continued commitment to community priorities. The report details progress across public safety, economic development, infrastructure, education, affordable housing, and workforce excellence over the past year, aligned with the goals outlined in the FY24-28 Strategic Plan. The results demonstrate that, while Enablealbemarle has much to celebrate, Enablealbemarle is also committed to confronting areas for improvement as Enablealbemarle continue the important work of fully realizing the vision of the FY24-28 Strategic Plan. The FY26 findings highlight meaningful progress across core priority areas, including public safety and climate action, workforce stability, community resilience, and economic development. The report reflects a year of substantial momentum toward long-term goals, strengthened by major investments, improved performance indicators, and continued accountability in managing public resources. This progress report underscores its commitment to improving the quality of life for all residents through strategic planning, community engagement, and cross-departmental collaboration. The report showcases key metrics and success stories across various initiatives, reflecting the collective efforts of the Board of Supervisors, County staff, and community partners. Its Strategic Plan serves as a roadmap that helps guide its decisions and actions to meet the needs of its community. This year's report highlights steady gains across public safety, economic development, affordable housing, climate action, infrastructure, workforce stabilization, and community resilience. These accomplishments result from a collaborative approach that unites the efforts of the Board of Supervisors and County staff. Here are a few of the report's notable highlights: * Public Safety: Emergency response times are improving, with 96% of rural Fire Rescue calls and over 90% of child and adult protective service referrals met on time. Enablealbemarle also launched its first independent Emergency Management Office. * Economic Growth: Major investments like AstraZeneca's $4.5 billion facility and Afton Scientific's expansion are bringing hundreds of new jobs. Enablealbemarle is also supporting more affordable housing, with over 2,500 new units since 2019 and nearly 2,900 more in the works. * Community & Environment: Enablealbemarle held a successful Climate Summit for local students, restored Biscuit Run Stream, and expanded invasive species management to 128 acres of parkland. Its climate projects are cutting greenhouse gas emissions and meeting Chesapeake Bay cleanup goals. * Better Infrastructure: Enablealbemarle built over 6,000 feet of new sidewalks and paths, improved public transit, and made its website more accessible. New parks and recreation projects, like the Darden Towe pickleball courts, are open for everyone to enjoy. * Education & Workforce: New schools and career academies are nearly complete, and over 110 County employees received job training this year. * County Services: Employee turnover is down to 5%, and new digital tools are making County services faster and more efficient. The FY24-28 Strategic Plan serves as a guiding vision for Albemarle County, setting clear goals and priorities that reflect the needs and aspirations of its community. It is an essential tool for resource allocation, performance measurement, and ensuring that Enablealbemarle remain accountable and transparent to you, its residents. By tracking and reporting on the progress of these goals, Enablealbemarle can make informed decisions that drive continuous improvement and foster a culture of excellence. The FY2026 report and all SPEAR metrics are available at albemarle.org.